Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 5781.

https://doi.org/10.1182/blood.V128.22.5781.5781

Published: 2016

Journal Articles

Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience

Hassan A. Aljasem, MBBS, MD, Hans A. Messner, MD PhD, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Auro Viswabandya, MD DM, Santhosh Thyagu, MBBS, MD DM, Uday Deotare, MD DM, Fotios V. Michelis, MD PhD

Blood (2016) 128 (22): 5838.

https://doi.org/10.1182/blood.V128.22.5838.5838

Published: 2016

Journal Articles

Refined Hepatic Grading System Improves Risk Stratification of Long-Term Outcomes in the Patients Developing Chronic Gvhd

Saud Alhayli, MBBS, Elizabeth Shin, Wilson Lam, MD, Uday Deotare, MD DM, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MBBS, MD DM, Auro Viswabandya, MD DM, Jeffrey H. Lipton, Hans A. Messner, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2016) 128 (22): 2235.

https://doi.org/10.1182/blood.V128.22.2235.2235

Published: 2016

Journal Articles

Comprehensive Analysis of Pre-Transplant Pulmonary Function Test Parameters Including FEV1, FVC, DLco, FEF50%/75%, Frc, RV and TLC As Prognostic Factors for Long-Term Outcomes after Allogeneic Transplantation

Wilson Lam, MD, Uday Deotare, MD DM, Jeffrey H. Lipton, MD PhD, Theodore Marras, MD MSc, Hans A. Messner, MD PhD, Fotios V. Michelis, MD PhD, Shikha Mittoo, MD MHS, Santhosh Thyagu, MBBS, MD DM, Auro Viswabandya, MD DM, Dennis Dong Hwan Kim, MD PhD

Blood (2016) 128 (22): 2253.

https://doi.org/10.1182/blood.V128.22.2253.2253

Published: 2016

Journal Articles

Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies

Manar Mohamed Ibrahim Khalil, MD MBBS, MRCP, Hans A. Messner, MD PhD, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Auro Viswabandya, MD DM, Santhosh Thyagu, MBBS, MD DM, Uday Deotare, MD DM, Fotios V. Michelis, MD PhD

Blood (2016) 128 (22): 4652.

https://doi.org/10.1182/blood.V128.22.4652.4652

Published: 2016

Journal Articles

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 3430.

https://doi.org/10.1182/blood.V128.22.3430.3430

Published: 2016

NARROW

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience

Refined Hepatic Grading System Improves Risk Stratification of Long-Term Outcomes in the Patients Developing Chronic Gvhd

Comprehensive Analysis of Pre-Transplant Pulmonary Function Test Parameters Including FEV1, FVC, DLco, FEF50%/75%, Frc, RV and TLC As Prognostic Factors for Long-Term Outcomes after Allogeneic Transplantation

Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Email alerts

ASH Publications

American Society of Hematology

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience

Refined Hepatic Grading System Improves Risk Stratification of Long-Term Outcomes in the Patients Developing Chronic Gvhd

Comprehensive Analysis of Pre-Transplant Pulmonary Function Test Parameters Including FEV1, FVC, DLco, FEF50%/75%, Frc, RV and TLC As Prognostic Factors for Long-Term Outcomes after Allogeneic Transplantation

Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only